Angiogenesis
- Cat.No. Product Name Information
-
GC68390
α5β1 integrin agonist-1
-
GC68373
BLK-IN-2
-
GC68283
Etrolizumab
-
GC67940
BTK inhibitor 10
-
GC67857
(R)-Elsubrutinib
-
GC67708
PLN-1474
-
GC65909
Bexotegrast
Bexotegrast is a potent inhibitor of αΝβ6 integrin. Bexotegrast can be used for researching fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP) (extracted from patent WO2020210404A1, compound 5).
-
GC65597
Abciximab
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor.
-
GC65529
TRAP-6 amide
TRAP-6 amide is a PAR-1 thrombin receptor agonist peptide.
-
GC65455
c(phg-isoDGR-(NMe)k)
c(phg-isoDGR-(NMe)k) is a selective and potent α5β1-integrin ligand with an IC50 of 2.9 nM.
-
GC65439
GB-88
GB-88 is an oral, selective non-peptide antagonist of PAR2, inhibits PAR2 activated Ca2+ release with an IC50 of 2 ?M.
-
GC65312
AZ8838
AZ8838 is a potent, competitive, allosteric, orally active non-peptide small molecule antagonist of PAR2 with a pKi of 6.4 for hPAR2.
-
GC64979
I-191
I-191 is a potent, selective protease-activated receptor 2 (PAR2) antagonist.
-
GC64932
αvβ5 integrin-IN-1
αvβ5 integrin-IN-1 is a first potent and selective αvβ5 integrin inhibitor (pIC50 = 8.2) .
-
GC64819
Elsubrutinib
Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (BTK) inhibitor。The IC50 of Elsubrutinib for BTK catalytic domain is 0.18 μM.
-
GC64571
Sibrafiban
Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-prodrug of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist.
-
GC64360
BTK inhibitor 18
BTK inhibitor 18 is a potent, selective,orally active and covalent Btk inhibitor with a IC50 of 142 nM.
-
GC64347
Vorapaxar sulfate
Vorapaxar sulfate (SCH 530348 sulfate), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM).
-
GC64212
Valategrast hydrochloride
Valategrast hydrochloride (R-411) is a potent integrin α4β1 (VLA-4) and α4β7 dual antagonist.
-
GC64120
TAK-020
TAK-020 is a covalent Btk inhibitor, which becomes the clinical candidate.
-
GC63846
BIIB091
BIIB091 is a highly selective, reversible and orally active BTK inhibitor for treating autoimmune diseases.
-
GC63797
(S)-Sunvozertinib
(S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against EGFR exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC50=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively). (S)-Sunvozertinib also inhibits BTK.
-
GC49716
Cyclo(RGDyK) (trifluoroacetate salt)
A cyclic peptide ligand of αVβ3 integrin
-
GC49713
SIKVAV (acetate)
A laminin α1-derived peptide
-
GC49686
N-desmethyl Regorafenib N-oxide
An active metabolite of regorafenib
-
GC49562
4-methoxy Estrone
An active metabolite of estrone
-
GC63658
Atopaxar
Atopaxar (E5555) is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist.
-
GC63540
SCH79797
SCH79797 is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist.
-
GC63490
Valategrast
Valategrast (R-411 free base) is a potent and orally active integrin α4β1 (VLA-4) and α4β7 dual antagonist.
-
GC63232
Tolebrutinib
Tolebrutinib (SAR442168) is a potent, selective, orally active and brain-penetrant inhibitor of Bruton tyrosine kinase (BTK), with IC50s of 0.4 and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively.
-
GC63229
TL-895
TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively.
-
GC62872
BMS-587101
BMS-587101 is a potent and orally active antagonist of leukocyte function associated antigen-1 (LFA-1).
-
GC49433
Capsiate
A capsaicin analog with diverse biological activities
-
GC49358
Sildenafil Chlorosulfonyl
An intermediate in the synthesis of sildenafil
-
GC49349
O-Desethyl Sildenafil
A metabolite of sildenafil
-
GC49221
QLT0267
An ILK inhibitor
-
GC62614
SJF620 hydrochloride
SJF620 hydrochloride is a PROTAC connected by ligands for Cereblon and Btk with a DC50 of 7.9 nM. SJF620 contains a Lenalidomide analog for recruiting CRBN.
-
GC62566
αvβ1 integrin-IN-1 TFA
-
GC62515
Pirtobrutinib
Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM.
-
GC62498
BTK inhibitor 17
BTK inhibitor 17 is a potent and orally active irreversible BTK inhibitor with an IC50 of 2.1 nM.
-
GC62469
Protease-Activated Receptor-1, PAR-1 Agonist TFA
Protease-Activated Receptor-1, PAR-1 Agonist TFA is a selective proteinase-activated receptor1 (PAR-1) agonist peptide. Protease-Activated Receptor-1, PAR-1 Agonist TFA corresponds to PAR1 tethered ligand and which can selectively mimic theactions of thrombin via this receptor.
-
GC62397
RO0270608
RO0270608, the active metabolite of R411, is a dual alpha4beta1-alpha4beta7 (α4β1/α4β7) integrin antagonist.
-
GC62380
αvβ1 integrin-IN-1
αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM.
-
GC62255
N-piperidine Ibrutinib hydrochloride
N-piperidine Ibrutinib hydrochloride (Compound 1) is a reversible Ibrutinib derivative. N-piperidine Ibrutinib hydrochloride is a potent BTK inhibitor with IC50s of 51.0 and 30.7 nM for WT BTK and C481S BTK, respectively. N-piperidine Ibrutinib hydrochloride can be used as a BTK ligand in the synthesis of a series of PROTACs, such as SJF620. SJF620 is a potent PROTAC BTK degrader with a DC50 of 7.9 nM.
-
GC62182
Echistatin TFA
Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation.
-
GC62143
Carotegrast methyl
Carotegrast methyl (AJM300) is an orally active and selective α4 integrin antagonist.
-
GC62101
PAR-2-IN-1
PAR-2-IN-1 is a protease-activated receptor-2 (PAR2) signaling pathway inhibitor with anti-inflammatory and anticancer effects.
-
GC61777
RWJ-56110 dihydrochloride
RWJ-56110 dihydrochloride is a potent, selective, peptide-mimetic inhibitor of PAR-1 activation and internalization (binding IC50=0.44 uM) and shows no effect on PAR-2, PAR-3, or PAR-4.
-
GC61613
Integrin modulator 1
Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC50 of 9.8 nM for RGD-binding α4β1.
-
GC61520
Cilengitide TFA
Cilengitide is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptor, with IC50 values of 4 nM and 79 nM, respectively.
-
GC61501
FSLLRY-NH2 TFA
FSLLRY-NH2 TFA is a protease-activated receptor 2 (PAR2) inhibitor.
-
GC61456
Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA
Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA is a proteinase-activated receptor (PAR-3) agonist peptide.
-
GC48210
TRX-818 (sodium salt)
An anticancer compound
-
GC48195
trans-trismethoxy Resveratrol-d4
An internal standard for the quantification of trans-trismethoxy resveratrol
-
GC48078
Sildenafil-d3
An internal standard for the quantification of sildenafil
-
GC47980
Propionyl-L-carnitine-d3 (chloride)
An internal standard for the quantification of propionyl-L-carnitine
-
GC47966
PPACK (trifluoroacetate salt)
An antithrombin peptide
-
GC47965
Pomalidomide-d5
An internal standard for the quantification of pomalidomide
-
GC47582
Lupulone
A beta-acid
-
GC47454
IMS 2186
An anti-choroidal neovascularization agent
-
GC47398
Genistein-d4
An internal standard for the quantification of genistein
-
GC47328
Everolimus-d4
An internal standard for the quantification of everolimus
-
GC47234
Diosmetin-d3
An internal standard for the quantification of diosmetin
-
GC47163
D-2-Aminoglutarimide (hydrochloride)
A synthetic intermediate
-
GC46899
Axitinib-13C-d3
An internal standard for the quantification of axitinib
-
GC46583
3-Amino-2,6-Piperidinedione
An active metabolite of (±)-thalidomide
-
GC46474
18-Deoxyherboxidiene
A bacterial metabolite with antiangiogenic activity
-
GC61323
Tetrac
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities.
-
GC61316
tcY-NH2 TFA
tcY-NH2 ((trans-Cinnamoyl)-YPGKF-NH2) TFA is a potent selective PAR4 antagonist peptide.
-
GC61109
Natalizumab
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1).
-
GC60807
ENMD-1068 hydrochloride
Selective protease-activated receptor 2 (PAR2) anatagonist
-
GC60551
Acalabrutinib D4
-
GC60200
ILK-IN-3
ILK-IN-3 is an integrin linked kinase inhibitor with antitumor activity.
-
GC60197
Ibrutinib deacryloylpiperidine
Ibrutinib deacryloylpiperidine (IBT4A) is an impurity of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM.
-
GC60117
Cyclo(-RGDfK) TFA
Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.
-
GC60077
BIO5192 hydrate
BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor (Kd<10 pM).
-
GC50642
LDV
α4β1 (VLA-4) ligand
-
GC50325
BOP
BOP is a potent and selective dual α9β1/α4β1 integrin inhibitor with Kd values in the picomolar range.
-
GC50078
BIRT 377
Potent negative allosteric modulator of LFA-1
-
GC50075
BTT 3033
Selective inhibitor of integrin α2β1
-
GC39194
Ibrutinib D5
Ibrutinib D5 (PCI-32765 D5) is a deuterium labeled Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor.
-
GC39146
HIF-1 inhibitor-1
An inhibitor of HIF-1 signaling
-
GC38893
BMS-688521
BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC50 of 2.5 nM in the adhesion assay and an IC50 of 60 nM in the MLR assay.
-
GC38873
α2β1 Integrin Ligand Peptide TFA
-
GC38801
Irigenin
Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells.
-
GC38767
Deoxyshikonin
A natural products with anti-tumor activity
-
GC38731
2-Furoyl-LIGRLO-amide TFA
2-Furoyl-LIGRLO-amide TFA is a potent and selective proteinase-activated receptor 2 (PAR2) agonist with a pD2 value of 7.0.
-
GC45880
Cimetidine-d3
An internal standard for the quantification of cimetidine
-
GC45798
Rhein-13C4
An internal standard for the quantification of rhein
-
GC45769
Vandetanib-d6
An internal standard for the quantification of vandetanib
-
GC45767
Dovitinib-d8
An internal standard for the quantification of dovitinib
-
GC45688
STX140
An estrogen sulfamate
-
GC38375
Remibrutinib
Remibrutinib, is a potent and orally active bruton tyrosine kinase (BTK) inhibitor with an IC50 value of 1 nM.
-
GC38329
GB-110 hydrochloride
GB-110 hydrochloride is a potent, orally active, and nonpeptidic protease activated receptor 2 (PAR2) agonist.
-
GC38134
Parmodulin 2
Reversible inhibitor of PAR1mediated platelet activation
-
GC38128
c(phg-isoD-G-R-(NMe)k) TFA
-
GC38044
Fraxinellone
-
GA23350
PAR-3 (1-6) amide (human)
PAR-3 (1-6) amide (human) is a proteinase-activated receptor (PAR-3) agonist peptide.
-
GA21306
Cyclo(-Arg-Gly-Asp-D-Tyr-Lys)
c(RGDyK) has been radioiodinated or modified with chelators for use as radiopharmaceutical.
-
GC37975
α2β1 Integrin Ligand Peptide
α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells.